Portal de Periódicos da CAPES

Cutting Edge: Immunological Consequences and Trafficking of Human Regulatory Macrophages Administered to Renal Transplant Recipients

2011; American Association of Immunologists; Volume: 187; Issue: 5 Linguagem: Inglês

10.4049/jimmunol.1100762

1550-6606

James A. Hutchinson, Paloma Riquelme, Birgit Sawitzki, Stefan Tomiuk, Patrick Miqueu, Maaz Zuhayra, Hans‐Heinrich Oberg, Andreas Pascher, Ulf Lützen, Uwe Janßen, Christiane Broichhausen, Lutz Renders, Friedrich Thaiss, Ernst Scheuermann, E. Henze, Hans‐Dieter Volk, Lucienne Chatenoud, Robert I. Lechler, Kathryn J. Wood, Dieter Kabelitz, Hans J. Schlitt, Edward K. Geissler, F. Fändrich,

Adolescent and Pediatric Healthcare

Regulatory macrophages (M regs) were administered to two living-donor renal transplant recipients. Both patients were minimized to low-dose tacrolimus monotherapy within 24 wk of transplantation and subsequently maintained excellent graft function. After central venous administration, most M regs remained viable and were seen to traffic from the pulmonary vasculature via the blood to liver, spleen, and bone marrow. By 1 y posttransplantation, both patients displayed patterns of peripheral blood gene expression converging upon the IOT-RISET signature. Furthermore, both patients maintained levels of peripheral blood FOXP3 and TOAG-1 mRNA expression within the range consistent with nonrejection. It is concluded that M regs warrant further study as a potential immune-conditioning therapy for use in solid-organ transplantation. The results of this work are being used to inform the design of The ONE Study, a multinational clinical trial of immunomodulatory cell therapy in renal transplantation.